S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma
Autor: | Hirokazu Awaya, Taiji Kuwata, Teruyoshi Ishida, Tetsuzo Tagawa, Mitsuhiko Ohta |
---|---|
Rok vydání: | 2010 |
Předmět: |
Pulmonary and Respiratory Medicine
Pathology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Mediastinal tumor Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Tegafur Salvage Therapy Chemotherapy business.industry Granulation tissue Radiotherapy Dosage Thymus Neoplasms Middle Aged medicine.disease Thymectomy Thymic Basaloid Carcinoma Combined Modality Therapy Radiation therapy Drug Combinations Oxonic Acid medicine.anatomical_structure Oncology Carcinoma Basal Cell Female Cisplatin business Chemoradiotherapy |
Zdroj: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 5(4) |
ISSN: | 1556-1380 |
Popis: | platin (60 mg/m 2 on day 1) and oral administration of S-1 (40 mg/m 2 , twice a day, between days 1 and 14) administered concurrently with 50 Gy of radiation. Radiotherapy was directed to all tumors including metastatic lesions. After chemoradiotherapy, two cycles of consolidation chemotherapy were performed with cisplatin and S-1. The mediastinal tumor showed a 52% reduction in size, and the right hilar lymph nodes and pulmonary nodule disappeared completely. In a FDG-positron emission tomographic scan, although the mediastinal tumor still showed a slight uptake of FDG, the other lesions showed none (Figure 1B). The patient underwent extended thymectomy with partial resection of the left lung. The resected tumor was solid, with no cystic lesions. Microscopically, there were scattered tumor cells among hyalinized collagenous fibers. Granulation tissue was also seen in the tumor, suggesting that chemoradiotherapy had induced tumor cell degeneration. The patient has survived without recurrence for 11 months since surgery, to date. |
Databáze: | OpenAIRE |
Externí odkaz: |